Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE, a prominent radiopharmaceutical biotech company, and TerThera, a leading provider of GMP-grade Terbium-161, today announced a supply agreement for non-carrier-added (n.c.a.) Terbium-161 (Tb-161). Tb-161 is a novel medical radioisotope recognized for its distinct chemical properties and growing promise in radiopharmaceutical therapy. Under the terms of the agreement, TerThera will provide ITM with Good Manufacturing Practice (GMP)-compliant n.c.a. Tb-161. This supply is intended to support the advancement of ITM’s Terbium-based pipeline candidates, thereby enhancing ITM’s existing manufacturing capabilities established in collaboration with the Paul Scherrer Institute (PSI).
“By driving innovation across isotopes, targeting molecules, and cancer indications, ITM maintains its leadership in the rapidly evolving radiopharmaceutical industry,” stated Dr. Andrew Cavey, CEO of ITM. “We recognize the significant potential in Terbium-161 as a crucial new isotope for targeted radiopharmaceutical therapy, and our partnership with TerThera will enable us to progress its application within our pipeline. With this supply of Terbium-161, we are well-positioned to leverage its radiation properties to deliver meaningful advancements for individuals living with cancer.”
Currently, radiopharmaceuticals based on Tb-161 are undergoing clinical investigation for various types of cancers. Tb-161 is attracting considerable attention in the radiopharmaceutical field due to its unique emission profile. Similar to Lu-177, it emits medium-range beta particles and possesses a comparable half-life. However, Tb-161 also releases low-energy Auger and internal conversion electrons, providing highly localized radiation that can effectively target isolated cancer cells and micro-metastases while minimizing off-target effects.
“As industry interest in Terbium-161 increases, a secure and sustainable supply of this radionuclide is vital to support the development of new treatment options and strategies, and we consider this our core mission,” added Philippe van Overeem, CEO of TerThera. “ITM is a genuine innovator in the dynamic radiopharmaceutical sector, and we look forward to supplying them with our GMP-grade Terbium-161 as they advance their pipeline candidates and work towards bringing the benefits of this valuable isotope to patients.”
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to developing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to address the needs of cancer patients, clinicians, and our partners through excellence in the development, production, and global supply of medical radioisotopes. With improved patient benefit as its guiding principle, ITM is advancing a broad precision oncology pipeline, which includes multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging two decades of pioneering radiopharma expertise, a central industry position, and an established global network, ITM strives to provide patients with more effective targeted treatments to enhance clinical outcomes and quality of life.
About TerThera
TerThera is a company focused on radionuclide production, based in The Netherlands. The founders and staff of TerThera possess decades of experience in the nuclear medicine industry and are highly committed to bringing the innovative radionuclide Terbium-161 (Tb-161) to clinical use. TerThera is building a global platform, including GMP production facilities in Europe, USA, and Asia, to meet the growing demand for radionuclides in Radioligand Therapy (RLT).
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:
TerThera Contact
Attachment
